Dual-targeting CD30/PDL1 CAR-T therapy in Hodgkin lymphoma

CD30, a promising target for CAR-T therapy in Hodgkin lymphomaПодробнее

CAR T-cell therapy in B-cell malignanciesПодробнее

The Potential of CD30 CAR T Cell Therapy for the Treatment of CD30-Positive LymphomasПодробнее

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?Подробнее

CD30-Specific CAR T Cells in Patients With Relapsed/Refractory Hodgkin LymphomaПодробнее

Infusion of CD30 CAR T-cells following AuHCT in patients with lymphomaПодробнее

‘Off-the-shelf’ EBV-specific CAR-T cells for Hodgkin lymphomaПодробнее

CD30-directed CAR-Ts co-expressing CCR4 in R/R HL and CD30+ CTCLПодробнее

Opportunities and challenges for dual-targeting CAR-T therapy in ALLПодробнее

Phase 1 trial of CAR T-cell therapy for lymphomaПодробнее

Understanding CAR T Cell Therapy and Lymphoma | LRF WebinarsПодробнее

CAR-T in LymphomaПодробнее

Panel discussion on immune therapies for lymphoma - CAR T-cell therapy and the question of cureПодробнее

The promise of CD30-targeting cellular therapies in HLПодробнее

Immunotherapy Beyond CAR T-Cell TherapyПодробнее

Challenges of dual-targeted CAR T-cell therapyПодробнее

Evaluating dual-targeting CD19/22 CAR-T cells in patients with R/R ALLПодробнее

Carlos Ramos | ASH 2018 | CD30 CAR-T therapy for HLПодробнее

Winship Webinar: Updates in CAR T-Cell Therapy for Non-Hodgkin LymphomaПодробнее